Systemic lupus erythematosus: Clinical features in patients with a disease duration of over 10 years, first evaluation

A. J G Swaak, H. G. Van Den Brink, R. J T Smeenk, K. Manger, J. R. Kalden, S. Tosi, A. Marchesoni, Z. Domljan, B. Rozman, D. Logar, G. Pokorny, L. Kovacs, A. Kovacs, P. G. Vlachoyiannopoulos, H. M. Moutsopoulos, H. Chwalinska-Sadowska, B. Dratwianka, E. Kiss, N. Cikes, A. BranimirM. Schneider, R. Fischer, S. Bombardieri, M. Mosca, W. Graninger, J. S. Smolen

Research output: Contribution to journalArticle

79 Citations (Scopus)

Abstract

Objective. Most information available about the disease course of patients with systemic lupus erythematosus (SLE) is restricted to the first 5 yr after disease onset. Data about the disease course 10 yr after disease onset are rare. The aim of this multicentre study was to describe the outcome of SLE patients with a disease duration of > 10 yr. Methods. Outcome parameters were the SLE Disease Activity Index (SLEDAI), the European Consensus Lupus Activity Measure (ECLAM), the Systemic Lupus International Collaborative Clinics/American College of Rheumatology Damage Index (SLICC/ACR), a global damage index (DI) and required treatment. In 10 different European rheumatology centres, all SLE patients who were evaluated in the last 3 months of 1994, and who had been diagnosed with SLE at least 10 yr ago, were included in the study. Results. It should be stressed that our results are confined to a patient cohort, defined by a disease duration of at least 10 yr, and who are still under clinical care at the different centres in Europe. These SLE patients still showed some disease activity, related to symptoms of the skin and musculoskeletal systems, next to the presence of renal involvement. A total of 72% of the patients needed treatment with prednisolone (≤ 7.5 mg). The cumulative damage was overall related to clinical features of the central nervous system (14%) and renal involvement (14%), next to deforming arthritis (14%), osteoporosis (15%) and hypertension (40%). The prevalences of obesity, Cushing appearance and diabetes are highly suggestive that the ongoing treatment and that in the past might have had an impact on the total sum of end-organ damage. Conclusions. After 10 yr, a high proportion of patients in our cohort continued to show evidence of active disease, defined by the SLEDAI as well as ECLAM. The DI was related to the involvement of the central nervous system, renal involvement and the presence of hypertension.

Original languageEnglish
Pages (from-to)953-958
Number of pages6
JournalRheumatology
Volume38
Issue number10
DOIs
Publication statusPublished - Oct 1999

Fingerprint

Systemic Lupus Erythematosus
Kidney
Central Nervous System
Hypertension
Musculoskeletal System
Rheumatology
Rare Diseases
Prednisolone
Osteoporosis
Multicenter Studies
Arthritis
Therapeutics
Obesity
Skin

Keywords

  • Damage Index
  • Disease activity
  • ECLAM
  • SLE
  • SLEDAI

ASJC Scopus subject areas

  • Neuroscience(all)
  • Rheumatology

Cite this

Swaak, A. J. G., Van Den Brink, H. G., Smeenk, R. J. T., Manger, K., Kalden, J. R., Tosi, S., ... Smolen, J. S. (1999). Systemic lupus erythematosus: Clinical features in patients with a disease duration of over 10 years, first evaluation. Rheumatology, 38(10), 953-958. https://doi.org/10.1093/rheumatology/38.10.953

Systemic lupus erythematosus : Clinical features in patients with a disease duration of over 10 years, first evaluation. / Swaak, A. J G; Van Den Brink, H. G.; Smeenk, R. J T; Manger, K.; Kalden, J. R.; Tosi, S.; Marchesoni, A.; Domljan, Z.; Rozman, B.; Logar, D.; Pokorny, G.; Kovacs, L.; Kovacs, A.; Vlachoyiannopoulos, P. G.; Moutsopoulos, H. M.; Chwalinska-Sadowska, H.; Dratwianka, B.; Kiss, E.; Cikes, N.; Branimir, A.; Schneider, M.; Fischer, R.; Bombardieri, S.; Mosca, M.; Graninger, W.; Smolen, J. S.

In: Rheumatology, Vol. 38, No. 10, 10.1999, p. 953-958.

Research output: Contribution to journalArticle

Swaak, AJG, Van Den Brink, HG, Smeenk, RJT, Manger, K, Kalden, JR, Tosi, S, Marchesoni, A, Domljan, Z, Rozman, B, Logar, D, Pokorny, G, Kovacs, L, Kovacs, A, Vlachoyiannopoulos, PG, Moutsopoulos, HM, Chwalinska-Sadowska, H, Dratwianka, B, Kiss, E, Cikes, N, Branimir, A, Schneider, M, Fischer, R, Bombardieri, S, Mosca, M, Graninger, W & Smolen, JS 1999, 'Systemic lupus erythematosus: Clinical features in patients with a disease duration of over 10 years, first evaluation', Rheumatology, vol. 38, no. 10, pp. 953-958. https://doi.org/10.1093/rheumatology/38.10.953
Swaak, A. J G ; Van Den Brink, H. G. ; Smeenk, R. J T ; Manger, K. ; Kalden, J. R. ; Tosi, S. ; Marchesoni, A. ; Domljan, Z. ; Rozman, B. ; Logar, D. ; Pokorny, G. ; Kovacs, L. ; Kovacs, A. ; Vlachoyiannopoulos, P. G. ; Moutsopoulos, H. M. ; Chwalinska-Sadowska, H. ; Dratwianka, B. ; Kiss, E. ; Cikes, N. ; Branimir, A. ; Schneider, M. ; Fischer, R. ; Bombardieri, S. ; Mosca, M. ; Graninger, W. ; Smolen, J. S. / Systemic lupus erythematosus : Clinical features in patients with a disease duration of over 10 years, first evaluation. In: Rheumatology. 1999 ; Vol. 38, No. 10. pp. 953-958.
@article{878ce17f0f77401d87c47dc60ac881f3,
title = "Systemic lupus erythematosus: Clinical features in patients with a disease duration of over 10 years, first evaluation",
abstract = "Objective. Most information available about the disease course of patients with systemic lupus erythematosus (SLE) is restricted to the first 5 yr after disease onset. Data about the disease course 10 yr after disease onset are rare. The aim of this multicentre study was to describe the outcome of SLE patients with a disease duration of > 10 yr. Methods. Outcome parameters were the SLE Disease Activity Index (SLEDAI), the European Consensus Lupus Activity Measure (ECLAM), the Systemic Lupus International Collaborative Clinics/American College of Rheumatology Damage Index (SLICC/ACR), a global damage index (DI) and required treatment. In 10 different European rheumatology centres, all SLE patients who were evaluated in the last 3 months of 1994, and who had been diagnosed with SLE at least 10 yr ago, were included in the study. Results. It should be stressed that our results are confined to a patient cohort, defined by a disease duration of at least 10 yr, and who are still under clinical care at the different centres in Europe. These SLE patients still showed some disease activity, related to symptoms of the skin and musculoskeletal systems, next to the presence of renal involvement. A total of 72{\%} of the patients needed treatment with prednisolone (≤ 7.5 mg). The cumulative damage was overall related to clinical features of the central nervous system (14{\%}) and renal involvement (14{\%}), next to deforming arthritis (14{\%}), osteoporosis (15{\%}) and hypertension (40{\%}). The prevalences of obesity, Cushing appearance and diabetes are highly suggestive that the ongoing treatment and that in the past might have had an impact on the total sum of end-organ damage. Conclusions. After 10 yr, a high proportion of patients in our cohort continued to show evidence of active disease, defined by the SLEDAI as well as ECLAM. The DI was related to the involvement of the central nervous system, renal involvement and the presence of hypertension.",
keywords = "Damage Index, Disease activity, ECLAM, SLE, SLEDAI",
author = "Swaak, {A. J G} and {Van Den Brink}, {H. G.} and Smeenk, {R. J T} and K. Manger and Kalden, {J. R.} and S. Tosi and A. Marchesoni and Z. Domljan and B. Rozman and D. Logar and G. Pokorny and L. Kovacs and A. Kovacs and Vlachoyiannopoulos, {P. G.} and Moutsopoulos, {H. M.} and H. Chwalinska-Sadowska and B. Dratwianka and E. Kiss and N. Cikes and A. Branimir and M. Schneider and R. Fischer and S. Bombardieri and M. Mosca and W. Graninger and Smolen, {J. S.}",
year = "1999",
month = "10",
doi = "10.1093/rheumatology/38.10.953",
language = "English",
volume = "38",
pages = "953--958",
journal = "Rheumatology",
issn = "1462-0324",
publisher = "Oxford University Press",
number = "10",

}

TY - JOUR

T1 - Systemic lupus erythematosus

T2 - Clinical features in patients with a disease duration of over 10 years, first evaluation

AU - Swaak, A. J G

AU - Van Den Brink, H. G.

AU - Smeenk, R. J T

AU - Manger, K.

AU - Kalden, J. R.

AU - Tosi, S.

AU - Marchesoni, A.

AU - Domljan, Z.

AU - Rozman, B.

AU - Logar, D.

AU - Pokorny, G.

AU - Kovacs, L.

AU - Kovacs, A.

AU - Vlachoyiannopoulos, P. G.

AU - Moutsopoulos, H. M.

AU - Chwalinska-Sadowska, H.

AU - Dratwianka, B.

AU - Kiss, E.

AU - Cikes, N.

AU - Branimir, A.

AU - Schneider, M.

AU - Fischer, R.

AU - Bombardieri, S.

AU - Mosca, M.

AU - Graninger, W.

AU - Smolen, J. S.

PY - 1999/10

Y1 - 1999/10

N2 - Objective. Most information available about the disease course of patients with systemic lupus erythematosus (SLE) is restricted to the first 5 yr after disease onset. Data about the disease course 10 yr after disease onset are rare. The aim of this multicentre study was to describe the outcome of SLE patients with a disease duration of > 10 yr. Methods. Outcome parameters were the SLE Disease Activity Index (SLEDAI), the European Consensus Lupus Activity Measure (ECLAM), the Systemic Lupus International Collaborative Clinics/American College of Rheumatology Damage Index (SLICC/ACR), a global damage index (DI) and required treatment. In 10 different European rheumatology centres, all SLE patients who were evaluated in the last 3 months of 1994, and who had been diagnosed with SLE at least 10 yr ago, were included in the study. Results. It should be stressed that our results are confined to a patient cohort, defined by a disease duration of at least 10 yr, and who are still under clinical care at the different centres in Europe. These SLE patients still showed some disease activity, related to symptoms of the skin and musculoskeletal systems, next to the presence of renal involvement. A total of 72% of the patients needed treatment with prednisolone (≤ 7.5 mg). The cumulative damage was overall related to clinical features of the central nervous system (14%) and renal involvement (14%), next to deforming arthritis (14%), osteoporosis (15%) and hypertension (40%). The prevalences of obesity, Cushing appearance and diabetes are highly suggestive that the ongoing treatment and that in the past might have had an impact on the total sum of end-organ damage. Conclusions. After 10 yr, a high proportion of patients in our cohort continued to show evidence of active disease, defined by the SLEDAI as well as ECLAM. The DI was related to the involvement of the central nervous system, renal involvement and the presence of hypertension.

AB - Objective. Most information available about the disease course of patients with systemic lupus erythematosus (SLE) is restricted to the first 5 yr after disease onset. Data about the disease course 10 yr after disease onset are rare. The aim of this multicentre study was to describe the outcome of SLE patients with a disease duration of > 10 yr. Methods. Outcome parameters were the SLE Disease Activity Index (SLEDAI), the European Consensus Lupus Activity Measure (ECLAM), the Systemic Lupus International Collaborative Clinics/American College of Rheumatology Damage Index (SLICC/ACR), a global damage index (DI) and required treatment. In 10 different European rheumatology centres, all SLE patients who were evaluated in the last 3 months of 1994, and who had been diagnosed with SLE at least 10 yr ago, were included in the study. Results. It should be stressed that our results are confined to a patient cohort, defined by a disease duration of at least 10 yr, and who are still under clinical care at the different centres in Europe. These SLE patients still showed some disease activity, related to symptoms of the skin and musculoskeletal systems, next to the presence of renal involvement. A total of 72% of the patients needed treatment with prednisolone (≤ 7.5 mg). The cumulative damage was overall related to clinical features of the central nervous system (14%) and renal involvement (14%), next to deforming arthritis (14%), osteoporosis (15%) and hypertension (40%). The prevalences of obesity, Cushing appearance and diabetes are highly suggestive that the ongoing treatment and that in the past might have had an impact on the total sum of end-organ damage. Conclusions. After 10 yr, a high proportion of patients in our cohort continued to show evidence of active disease, defined by the SLEDAI as well as ECLAM. The DI was related to the involvement of the central nervous system, renal involvement and the presence of hypertension.

KW - Damage Index

KW - Disease activity

KW - ECLAM

KW - SLE

KW - SLEDAI

UR - http://www.scopus.com/inward/record.url?scp=6544275277&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=6544275277&partnerID=8YFLogxK

U2 - 10.1093/rheumatology/38.10.953

DO - 10.1093/rheumatology/38.10.953

M3 - Article

C2 - 10534545

AN - SCOPUS:6544275277

VL - 38

SP - 953

EP - 958

JO - Rheumatology

JF - Rheumatology

SN - 1462-0324

IS - 10

ER -